FY2026 Earnings Estimate for PMVP Issued By HC Wainwright

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – HC Wainwright issued their FY2026 earnings estimates for shares of PMV Pharmaceuticals in a research report issued on Friday, September 19th. HC Wainwright analyst R. Burns expects that the company will earn ($1.63) per share for the year. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.06) per share.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02).

PMV Pharmaceuticals Trading Up 6.5%

PMVP opened at $1.31 on Monday. The company’s fifty day moving average price is $1.41 and its two-hundred day moving average price is $1.17. The company has a market cap of $69.42 million, a price-to-earnings ratio of -0.83 and a beta of 1.52. PMV Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.84.

Insiders Place Their Bets

In other PMV Pharmaceuticals news, CEO David Henry Mack sold 58,411 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $61,915.66. Following the completion of the transaction, the chief executive officer owned 536,133 shares in the company, valued at $568,300.98. This trade represents a 9.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Orbimed Advisors Llc sold 500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $1.80, for a total transaction of $900,000.00. Following the completion of the transaction, the insider owned 5,975,291 shares of the company’s stock, valued at $10,755,523.80. This trade represents a 7.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 614,627 shares of company stock worth $1,021,505 over the last quarter. 7.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PMVP. Shay Capital LLC purchased a new position in PMV Pharmaceuticals during the 2nd quarter valued at $26,000. Squarepoint Ops LLC lifted its stake in PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company’s stock valued at $110,000 after acquiring an additional 29,722 shares during the period. Northern Trust Corp lifted its stake in shares of PMV Pharmaceuticals by 23.2% in the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock worth $162,000 after purchasing an additional 20,190 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of PMV Pharmaceuticals by 128.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 263,059 shares of the company’s stock worth $279,000 after purchasing an additional 148,021 shares during the period. Finally, Peapod Lane Capital LLC raised its stake in PMV Pharmaceuticals by 9.8% during the 1st quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company’s stock worth $533,000 after acquiring an additional 43,626 shares during the period. 90.20% of the stock is owned by hedge funds and other institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.